Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ORTHOCELL LIMITED Director's Dealing 2019

Jul 10, 2019

65477_rns_2019-07-10_cbf69aea-34a5-49c6-93b9-e7fa8aa47eff.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.s

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and made be made public.

Introduced 30/09/2001

Introduced 30/09/2001
Name of entity: Orthocell Limited
ABN: 57 118 897 135

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

director for the purposes of section 205G of the Corporations Act.
Name of Director: Stewart Washer
Date of last notice: 7 June 2019

Part 1 - Change of director’s relevant interests in securities

Note: In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust. In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest Direct and Indirect
Nature of indirect interest (including
registered holder)
Note: Provide details of the circumstances giving rise to
the relevant interest.
Dr Stewart James Washer & Dr Patrizia Derna
Washer Fund>
(Dr Washer is a trustee and beneficiary of the
superannuation fund)
Dr Stewart James Washer & Dr Patrizia Derna
Washer
(Dr Washer is a trustee and beneficiary of the Trust)
Mal Washer Nominees Pty Ltd Family A/C>
(Dr Washer is a trustee and beneficiary of the trust)
Date of change 11 July 2019
No. of securities held prior to change
Dr Stewart James Washer & Dr Patrizia Derna
Washer Fund>
(Dr Washer is a trustee and beneficiary of the
superannuation fund)
Dr Stewart James Washer & Dr Patrizia Derna
Washer
(Dr Washer is a trustee and beneficiary of the Trust)
314,417 Ordinary Shares
391,108 Ordinary Shares
1,850,000 Unlisted Options
exercisable at $0.395 expiring 8 May 2021 (vesting
conditions set out in NOM for General Meeting held on 7
May 2018)
  • See chapter 19 for defined terms

Appendix 3Y pg. 1

Appendix 3Y Change of Director’s Interest Notice

Mal Washer Nominees Pty Ltd Family A/C>
(Dr Washer is a trustee and beneficiary of the trust)
235,994 Ordinary Shares
95,842 Unlisted Warrants
exercisable at $0.58 on or before 19 November 2020
Class changed Ordinary Shares
Number acquired 26,316
Number disposed -
Value/Consideration
Note: If consideration is non-cash, provide details and
estimated valuation
Issued in lieu of fees based on formula set out in
Notice of General Meeting lodged on ASX
18/04/2019 being $0.475 per share
No. of securities held after change
Dr Stewart James Washer & Dr Patrizia Derna
Washer Fund>
(Dr Washer is a trustee and beneficiary of the
superannuation fund)
Dr Stewart James Washer & Dr Patrizia Derna
Washer
(Dr Washer is a trustee and beneficiary of the Trust)
Mal Washer Nominees Pty Ltd Family A/C>
(Dr Washer is a trustee and beneficiary of the trust)
314,417 Ordinary Shares
417,424 Ordinary Shares
1,850,000 Unlisted Options
exercisable at $0.395 expiring 8 May 2021 (vesting
conditions set out in NOM for General Meeting held on 7
May 2018)
235,994 Ordinary Shares
95,842 Unlisted Warrants
exercisable at $0.58 on or before 19 November 2020
Nature of change
Example: on-market trade, off-market trade, exercise of
options, issue of securities under dividend reinvestment
plan, participation in buy-back
Shares issued in lieu of fees for June 2019 as
approved by shareholders at a general meeting
on 20 May 2019

Part 2 - Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract N/A
Nature of interest N/A
Name of registered holder (if issued securities) N/A
Date of change N/A
No. and class of securities to which interest related prior
to change
Note: Details are only required for a contract in relation to which the
interest has changed
N/A
Interest acquired N/A
Interest disposed N/A
Value/Consideration N/A
  • See chapter 19 for defined terms

Appendix 3Y pg. 2

Appendix 3Y Change of Director’s Interest Notice

Note: if consideration is non-cash, provide details and an estimated valuation Interest after changes N/A

Part 3 – Closed Period

Part 3 – Closed Period
Were the interests in the securities or contracts
detailed above traded during a +closed period
where prior written clearance was required?
No
If so, was prior written clearance provided to
allow the trade to proceed during this period?
N/A
If prior written clearance was provided, on
what date was this provided?
N/A
  • See chapter 19 for defined terms

Appendix 3Y pg. 3

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.s

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and made be made public.

Introduced 30/09/2001

Name of entity: Orthocell Limited
ABN: 57 118 897 135

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

director for the purposes of section 205G of the Corporations Act.
Name of Director: Matthew Callahan
Date of last notice: 7 June 2019

Part 1 - Change of director’s relevant interests in securities

Note: In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust. In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest Direct and Indirect
Nature of indirect interest (including
registered holder)
Note: Provide details of the circumstances
giving rise to the relevant interest.
Mr Callahan is a founder and director of Stone Ridge
Ventures Pty Ltd which is the manager of the SRV Tech
Trust, a venture capital fund. Mr Callahan is considered
to have a relevant interest in these shares due to his
position as a director or shareholder of the respective
trustee companies and holds a beneficial interest in the
SRV Trust. The SRV Trust is the carry trust for the SRV
Tech Trust
Mr Callahan is a director of the Trustee and a beneficiary
of the Shenasaby trust
Mr Callahan is a director of the Trustee and a beneficiary
of the Shenasaby trust
Date of change 11 July 2019
No. of securities held prior to change
SRV Custodians Pty Ltd

SRV Nominees Pty Ltd

Shenasaby Investments Pty Ltd
7,570,000 Ordinary Shares
649,177 Ordinary Shares
12,500 Ordinary Shares
  • See chapter 19 for defined terms

Appendix 3Y pg. 1

Appendix 3Y Change of Director’s Interest Notice

Appendix 3Y
Change of Director’s Interest Notice
Shenasaby Investments Pty Ltd as
trustee for the Shenasaby Trust
398,710 Ordinary Shares
1,850,000 Unlisted Options exercisable at $0.395
expiring 8 May 2021 (vesting conditions set out in NOM
for General Meeting held on 7 May 2018)
Class changed Ordinary Shares
Number acquired 21,053
Number disposed -
Value/Consideration
Note: If consideration is non-cash, provide
details and estimated valuation
Issued in lieu of fees based on formula set out in Notice
of General Meeting lodged on ASX 18/04/2019 being
$0.475 per share
No. of securities held after change
SRV Custodians Pty Ltd

SRV Nominees Pty Ltd

Shenasaby Investments Pty Ltd

Shenasaby Investments Pty Ltd as
trustee for the Shenasaby Trust
7,570,000 Ordinary Shares
649,177 Ordinary Shares
12,500 Ordinary Shares
419,763 Ordinary Shares
1,850,000 Unlisted Options exercisable at $0.395
expiring 8 May 2021 (vesting conditions set out in NOM
for General Meeting held on 7 May 2018)
Nature of change
Example: on-market trade, off-market trade,
exercise of options, issue of securities under
dividend reinvestment plan, participation in
buy-back
Shares issued in lieu of fees for June 2019 as approved
by shareholders at a general meeting on 20 May 2019

Part 2 - Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract N/A
Nature of interest N/A
Name of registered holder (if issued securities) N/A
Date of change N/A
No. and class of securities to which interest related prior
to change
Note: Details are only required for a contract in relation to which the
interest has changed
N/A
Interest acquired N/A
  • See chapter 19 for defined terms

Appendix 3Y pg. 2

Appendix 3Y Change of Director’s Interest Notice

Appendix 3Y
Change of Director’s Interest Notice
Interest disposed N/A
Value/Consideration
Note: if consideration is non-cash, provide details and an estimated
valuation
N/A
Interest after changes N/A

Part 3 – Closed Period

Part 3 – Closed Period
Were the interests in the securities or contracts
detailed above traded during a +closed period
where prior written clearance was required?
No
If so, was prior written clearance provided to
allow the trade to proceed during this period?
N/A
If prior written clearance was provided, on
what date was this provided?
N/A
  • See chapter 19 for defined terms

Appendix 3Y pg. 3

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity Orthocell Limited ABN 57 118 897 135

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director Lars Lidgren
Date of last notice 7 June 2019

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest Direct and Indirect
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
JP Morgan Nominees Australia Limited
Diamonex Ltd
managed by
Banque Carnegie Luxembourg SA Nominees
(Professor Lidgren is a director of Diamonex Ltd)
Algora AB
(Professor Lidgren is a director of Algora AB
Ltd)
Date of change 11 July 2019
No. of securities held prior to change
JP Morgan Nominees Australia Limited
Diamonex Ltd
managed by
Banque Carnegie Luxembourg SA Nominees
(Professor Lidgren is a director of Diamonex
Ltd)
Algora AB
(Professor Lidgren is a director ofAlgora AB
Ltd)
357,449 Ordinary Shares
768,091 Ordinary Shares
54,767 Unlisted Warrants exercisable at $0.58 on
or before 19 November 2020
300,000 Unlisted Options exercisable at $0.395
expiring 8 May 2021 (vesting conditions set out
in NOM for General Meeting held on 7 May
2018)
  • See chapter 19 for defined terms.

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Class Ordinary Shares
Number acquired 7,895
Number disposed -
Value/Consideration
Note: If consideration is non-cash, provide details and estimated valuation
Issued in lieu of fees based on formula set out
in Notice of General Meeting lodged on ASX
18/04/2019 being $0.475 per share
No. of securities held after change
JP Morgan Nominees Australia Limited
Diamonex Ltd
managed by
Banque Carnegie Luxembourg SA Nominees
(Professor Lidgren is a director of Diamonex
Ltd)
Algora AB
(Professor Lidgren is a director ofAlgora AB
Ltd)
365,344 Ordinary Shares
768,091 Ordinary Shares
54,767 Unlisted Warrants exercisable at $0.58
on or before 19 November 2020
300,000 Unlisted Options exercisable at
$0.395 expiring 8 May 2021 (vesting
conditions set out in NOM for General Meeting
held on 7 May 2018)
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue of
securities under dividend reinvestment plan, participation in buy-back
Shares issued in lieu of fees for June 2019 as
approved by shareholders at a general
meeting on 20 May 2019

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.


in thispart.
Detail of contract N/A
Nature of interest N/A
Name of registered holder
(if issued securities)
N/A
Date of change N/A
No. and class of securities to which interest
related prior to change
Note: Details are only required for a contract in relation to which the interest
has changed
N/A
Interest acquired N/A
  • See chapter 19 for defined terms.

Appendix

3Y

2

Page

Appendix 3Y Change of Director’s Interest Notice

Interest disposed N/A
Value/Consideration
Note: If consideration is non-cash, provide details and an estimated valuation
N/A
Interest after change N/A

Part 3 Closed Period

art 3 Closed Period
Were the interests in the securities or contracts detailed
above traded during a +closed period where prior written
clearance was required?
No
If so, was prior written clearance provided to allow the trade
to proceed during this period?
N/A
If prior written clearance was provided, on what date was this
provided?
N/A
  • See chapter 19 for defined terms.

Appendix 3Y Page 3

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity Orthocell Limited

ABN 57 118 897 135

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director Qi Xiao Zhou
Date of last notice 7 June 2019

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest Direct
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Date of change 11 July 2019
No. of securities held prior to change
Qi Xiao Zhou
6,087,817 Ordinary Shares
54,767 Unlisted Warrants exercisable at
$0.58 on or before 19 November 2020
300,000 Unlisted Options exercisable at
$0.395 expiring 8 May 2021 (vesting
conditions set out in NOM for General
Meeting held on 7 May 2018)
Class Ordinary Shares
Number acquired 7,895
Number disposed -
  • See chapter 19 for defined terms.

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration
Note: If consideration is non-cash, provide details and estimated
valuation Issued in lieu of fees based on formula set
out in Notice of General Meeting lodged on
ASX 18/04/2019 being $0.475 per share
No. of securities held after change
Qi Xiao Zhou
6,095,712 Ordinary Shares
54,767 Unlisted Warrants exercisable at $0.58 on or
before 19 November 2020
300,000 Unlisted Options exercisable at $0.395
expiring 8 May 2021 (vesting conditions set out in
NOM for General Meeting held on 7 May 2018)
Nature of change
Example: on-market trade, off-market trade, exercise of options,
issue
of
securities
under
dividend
reinvestment
plan,
participation in buy-back
Shares issued in lieu of fees for June 2019 as
approved by shareholders at a general meeting on
20 May 2019

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract N/A
Nature of interest N/A
Name of registered holder
(if issued securities)
N/A
Date of change N/A
No. and class of securities to which
interest related prior to change
Note: Details are only required for a contract in relation to which the
interest has changed
N/A
Interest acquired N/A
Interest disposed N/A
Value/Consideration
Note: If consideration is non-cash, provide details and an estimated
valuation
N/A
Interest after change N/A
  • See chapter 19 for defined terms.

Appendix 3Y Page 2

Appendix 3Y Change of Director’s Interest Notice

Part 3 Closed Period

Part 3 Closed Period
Were the interests in the securities or contracts
detailed above traded during a +closed period
where prior written clearance was required?
No
If so, was prior written clearance provided to
allow the trade to proceed during this period?
N/A
If prior written clearance was provided, on what
date was this provided?
N/A
  • See chapter 19 for defined terms.

Appendix 3Y Page 3